It is my great pleasure to welcome you to the 8th International Symposium on Kallikreins and Kallikrein-Related
Peptidases (ISK2019), which will be held in Prague, Czech Republic from 25 to 27 September 2019.
The 8th edition of the international symposium will offer a multidisciplinary programme of presentations on the latest developments covering all areas of kallikrein research and clinical applications.
A major theme of this symposium will highlight the utility of genetic models to unravel the role of kallikrein proteases in normal physiology and disease.
The topics will range from themes such as KLK genetics and genomics, KLKs in physiology and pathophysiology: e.g. skin and brain disorders, inflammatory and infectious diseases, KLKs in malignant diseases (biomarkers and pathophysiology), KLKs in tissue and cell signaling, structural and functional aspects of Kallikreins (substrates and inhibitors), and to a therapeutic potential of KLKs. For a list of invited speakers and main topics scroll down the website.
Our capital, Prague, is a charming city situated in the very heart of Europe. It has a rich history, magnificent architecture (known as the city of "hundred spires") and a unique culture influenced by various styles that have appeared over the centuries. The city has hosted or has been a "beloved" place for famous personalities like J. Kepler, W. A. Mozart, R. Descartes, P. I. Tchaikovsky, A. Einstein, F. Kafka and many others.
We are looking forward to meeting you in Prague in September 2019.
on behalf of the local organizing committee
- KLK genetics and beyond (including genetics, genomics, other ‘omics’ technologies)
KLKs in physiology and pathophysiology (including topics from variety of physiologic
systems and diseases including those originating in the skin, brain, immune system,
inflammation, infectious diseases etc.)
- KLKs in malignant diseases (the topic includes also biomarkers and pathophysiology)
- KLKs in tissue and cell signaling
- Structural and functional aspects of kallikreins, their substrates and inhibitors
- Therapeutic potential of KLKs (the topic may include also drug design)